Mobile

A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002045-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the safety, tolerability, and antiviral activity of GS-9131 administered orally as ten consecutive once-daily doses in antiretroviral-naive subjects chronically infected with HIV-1.

Critère d'inclusion

  • Antiretroviral treatment–naive subjects chronically infected with HIV-1

Liens